June 20, 2017
According to new research presented at the 2017 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), prostate-specific molecular imaging could improve clinical management, especially in patients whose cancer returns.
The study includes data from four Australian medical centres and several hundred patients who were examined over a period of 18 months. All study patients underwent PET/CT with an injected imaging agent comprised of a tiny amount of gallium-68 (Ga-68) and prostate specific membrane antigen (PSMA). The imaging agent zeroes in on areas where the PSMA protein is over-expressed on cell surfaces. The PSMA over-expression emits a signal that is picked up by the PET scanner enabling it to create a more accurate map of the disease.